Skip to main content
SpringerLink
Log in

Sucroferric Oxyhydroxide: A Review in Hyperphosphataemia in Chronic Kidney Disease Patients Undergoing Dialysis

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Sucroferric oxyhydroxide (Velphoro®), an iron-based oral phosphate binder, is available for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. In a pivotal phase III trial, sucroferric oxyhydroxide 1000–3000 mg/day for 24 weeks was noninferior to sevelamer carbonate 4800–14,400 mg/day with regard to lowering serum phosphorus levels. Additionally, sucroferric oxyhydroxide at maintenance dosages was significantly more effective than low dosage sucroferric oxyhydroxide (250 mg/day) with regard to maintaining controlled serum phosphorus levels during weeks 24–27 of treatment. Sucroferric oxyhydroxide had a numerically lower mean daily pill burden and better treatment adherence than sevelamer carbonate. Treatment with sucroferric oxyhydroxide was generally well tolerated over 24 weeks’ treatment, with the most frequently reported treatment-emergent adverse events being mild, transient diarrhoea and discoloured faeces. In a 28-week extension study, the efficacy and tolerability profile of sucroferric oxyhydroxide remained similar to sevelamer carbonate for up to 52 weeks. In conclusion, sucroferric oxyhydroxide is a valuable treatment option for hyperphosphataemia in CKD patients on dialysis, providing an effective and generally well tolerated noncalcium-based phosphate binder therapy with a lower pill burden than sevelamer carbonate and the potential for improved treatment adherence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1–130.

    Google Scholar 

  2. Covic A, Rastogi A. Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrol. 2013;14:153.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Ketteler M, Wuthrich RP, Floege J. Management of hyperphosphataemia in chronic kidney disease-challenges and solutions. Clin Kidney J. 2013;6(2):128–36.

    Article  Google Scholar 

  4. Cupisti A, Gallieni M, Rizzo MA, et al. Phosphate control in dialysis. Int J Nephrol Renovasc Dis. 2013;6:193–205.

    Article  PubMed Central  PubMed  Google Scholar 

  5. National Institute for Health and Care Excellence. Hyperphosphataemia in chronic kidney disease: management of hyperphosphataemia in patients with stage 4 or 5 chronic kidney disease (NICE clinical guideline 157). 2013. http://www.nice.org.uk. Accessed 23 Feb 2015.

  6. Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol. 2006;1(4):697–703.

    Article  CAS  PubMed  Google Scholar 

  7. Fresenius Medical Care North America. Velphoro (sucroferric oxyhydroxide) chewable tablet for oral use: US prescribing information. 2014. http://www.velphoro.us. Accessed 23 Feb 2015.

  8. Vifor Fresenius Medical Care Renal Pharma France. Velphoro 500 mg chewable tablets: EU summary of product characteristics. 2015. http://www.ema.europa.eu. Accessed 23 Feb 2015.

  9. Kissei Pharmaceutical Co. Ltd. New drug application submitted for “PA21 (development code)” for treatment of hyperphosphatemia [media release]. 19 Nov 2014. http://kissei.co.jp/e_contents.

  10. Wilhelm M, Gaillard S, Rakov V, et al. The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro. Clin Nephrol. 2014;81(04):251–8.

    Article  CAS  PubMed  Google Scholar 

  11. Hergesell O, Ritz E. Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant. 1999;14(4):863–7.

    Article  CAS  PubMed  Google Scholar 

  12. Lanz M, Baldischweiler J, Kriwet B, et al. Chewability testing in the development of a chewable tablet for hyperphosphatemia. Drug Dev Ind Pharm. 2014;40(12):1623–31.

    Article  CAS  PubMed  Google Scholar 

  13. Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol. 2010;74(1):4–11.

    Article  CAS  PubMed  Google Scholar 

  14. Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86:638–47.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Floege J, Covic AC, Ketteler M, et al. Long-term effects of iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015. doi:10.1093/ndt/gfv006.

    Google Scholar 

  16. Sprague SM, Covic A, Floege J, et al. Concomitant intravenous iron use drives changes in iron indices in a phase 3 study of PA21 [abstract plus poster]. In: National Kidney Foundation 2014 Spring Clinical Meeting. 2014.

  17. Chong E, Kalia V, Willsie S, et al. Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects. J Nephrol. 2014;27(6):659–66.

    Article  PubMed Central  Google Scholar 

  18. Levesque V, Chong EMF, Moneuse P. Post-hoc analysis of pharmacodynamic interaction of PA21 with statins in a phase 3 study of PA21 in dialysis patients with hyperphosphatemia [abstract no. SA-PO568]. In: American Society of Nephrology Kidney Week 2013. 2013.

  19. Floege J, Botha J, Chong E, et al. PA21 does not interact with oral vitamin D receptor agonists: a post hoc analysis of a phase 3 study [abstract no. SP257]. Nephrol Dial Transplant. 2014;29(Suppl 3):iii157.

    Google Scholar 

  20. Wuthrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol. 2013;8(2):280–9.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Vifor Inc. A phase 3 study to investigate the safety and efficacy of PA21, a phosphate binder, in dialysis patients [ClinicalTrials.gov identifier NCT01324128]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/. Accessed 23 Feb 2015.

  22. Covic AC, Floege J, Ketteler M, et al. Efficacy and safety of PA21, a novel iron-based phosphate binder in CKD patients on peritoneal- and hemodialysis [abstract]. In: 15th Congress of the International Society of Peritoneal Dialysis. 2014.

  23. Floege J. Efficacy and safety of the novel iron-based phosphate binder PA21 in peritoneal- and hemodialysis-dependent CKD patients [abstract plus poster]. In: 11th European Peritoneal Dialysis Meeting. 2013.

  24. Covic A, Ketteler M, Rastogi A, et al. Comparison of safety profiles of PA21 and sevelamer carbonate in a post hoc analysis of a phase 3 study [abstract no. SP245]. Nephrol Dial Transplant. 2014;29(Suppl 3):iii153.

    Google Scholar 

  25. Malberti F. Hyperphosphataemia: treatment options. Drugs. 2013;73(7):673–88.

    Article  CAS  PubMed  Google Scholar 

  26. Nastou D, Fernandez-Fernandez B, Elewa U, et al. Next-generation phosphate binders: focus on iron-based binders. Drugs. 2014;74(8):863–77.

    Article  CAS  PubMed  Google Scholar 

  27. Chiu YW, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089–96.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Wang S, Alfieri T, Ramakrishnan K, et al. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol Dial Transplant. 2014;29(11):2092–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Gutzwiller FS, Braunhofer PG, Szucs TD, et al. Health economic evaluation of non-calcium-based phosphate binders in Scotland [abstract no. SP596]. Nephrol Dial Transplant. 2014;29(Suppl 3):iii271.

    Google Scholar 

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit. Sarah Greig and Greg Plosker are salaried employees of Adis/Springer.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand

    Sarah L. Greig & Greg L. Plosker

Authors
  1. Sarah L. Greig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Greg L. Plosker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah L. Greig.

Additional information

The manuscript was reviewed by: B. S. Spinowitz, Nephrology, New York Hospital, Queens, New York, NY, USA; R. P. Wüthrich, Division of Nephrology, University Hospital, Zurich, Switzerland.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Greig, S.L., Plosker, G.L. Sucroferric Oxyhydroxide: A Review in Hyperphosphataemia in Chronic Kidney Disease Patients Undergoing Dialysis. Drugs 75, 533–542 (2015). https://doi.org/10.1007/s40265-015-0366-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0366-1

Keywords

Search

Navigation